Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 2
Submit an article Journal homepage
228
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL)

Francesco Malfonaa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5353-6584
ORCID Icon,
Anna Maria Testia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Maria Luisa Moletia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Luigi Petruccia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Lucia Leccisottib Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
,
Maurizio Martellia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
&
Alice Di Roccoa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
 show all
Pages 483-486 | Received 06 Aug 2021, Accepted 02 Sep 2021, Published online: 06 Oct 2021

References

  • Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–327.
  • Dunleavy K, Pittaluga S, Maeda LS, Advani R, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416.
  • Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020;189(5):826–843.
  • Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with Second-Line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018;24(10):2133–2138.
  • Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated Central nervous system relapse of systemic non-Hodgkin lymphoma: an international primary CNS lymphoma collaborative group report. Blood. 2008;111(3):1085–1093.
  • Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11(1):28–40.
  • Zinzani PL, Martelli M, Bertini M, et al. International extranodal lymphoma study group (IELSG). induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258–1264.
  • Ferreri AJ, Cwynarski K, Pulczynski E, et al. International extranodal lymphoma study group (IELSG). chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-27–e227.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
  • Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–3156.
  • Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–445.
  • Chamoun K, Choquet S, Boyle E, et al. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology. 2017;88(1):101–102.
  • Grommes C, Gavrilovic IT, Kaley TJ, et al. Updated results of single-agent ibrutininb in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Abstract J Clin Oncol. 2017;NCT02315326.
  • Lauer EM, Waterhouse M, Braig M, et al. Ibrutinib in patients with relapsed/refractory Central nervous system lymphoma: a retrospective single-Centre analysis. Br J Haematol. 2020;190(2):e110–e114. Jul;
  • Lewis KL, Chin CK, Manos K, et al. Ibrutinib for Central nervous system lymphoma: the australasian lymphoma alliance/MD anderson cancer center experience. Br J Haematol. 2021;192(6):1049–1053.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.